Economic impact of non-persistence to antidepressant therapy in the Quebec community-dwelling elderly population

Journal of Affective Disorders

Volumn 115, Issue 1-2, 2009, Pages 160-166

  Tournier, Marie ^a,b,c   Moride, Yola ^a,b,d   Crott, Ralph ^e   Galbaud du Fort, Guillaume ^a   Ducruet, Thierry ^a,d  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITÉ DE BORDEAUX   (France)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

^e BELGIAN HEALTH CARE KNOWLEDGE CENTRE KCE   (Belgium)

Author keywords

Antidepressants; Drug utilization; Elderly; Health care costs; Persistence

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; FLUOXETINE; FLUVOXAMINE; NEFAZODONE; PAROXETINE; SERTRALINE; TRAZODONE; VENLAFAXINE;

AGED; ARTICLE; CANADA; COHORT ANALYSIS; COMMUNITY SAMPLE; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DRUG COST; ECONOMIC ASPECT; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH PROGRAM; HEALTH SERVICE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MEDICAL SERVICE; OBSERVATIONAL STUDY; OUTPATIENT DEPARTMENT; POPULATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION;

EID: 62749199746     PISSN: 01650327     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jad.2008.07.004     Document Type: Article

References (24)

1. Alexopoulos G.S. New concepts for prevention and treatment of late-life depression. Am J Psychiatry 158 (2001) 835-838
2. Alexopoulos G.S. Depression in the elderly. Lancet 365 (2005) 1961-1970
3. Anderson I.M., and Tomenson B.M. Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis. BMJ 310 (1995) 1433-1438
4. Barrett B., Byford S., and Knapp M. Evidence of cost-effective treatments for depression: a systematic review. J Affect Disord 84 (2005) 1-13
5. Bull S.A., Hunkeler E.M., Lee J.Y., Rowland C.R., Williamson T.E., Schwab J.R., and Hurt S.W. Discontinuing or switching selective serotonin-reuptake inhibitors. Ann Pharmacother 36 (2002) 578-584
6. Crott R., and Gilis P. Economic comparisons of the pharmacotherapy of depression: an overview. Acta Psychiatr Scand 97 (1998) 241-252
7. Edwards J.G., and Anderson I. Systematic review and guide to selection of selective serotonin reuptake inhibitors. Drugs 57 (1999) 507-533
8. Fischer L.R., Wei F., Rolnick S.J., Jackson J.M., Rush W.A., Garrard J.M., Nitz N.M., and Luepke L.J. Geriatric depression, antidepressant treatment, and healthcare utilization in a health maintenance organization. J Am Geriatr Soc 50 (2002) 307-312
9. Flint A.J., and Rifat S.L. Two-year outcome of elderly patients with anxious depression. Psychiatry Res 66 (1997) 23-31
10. Geddes J.R., Carney S.M., Davies C., Furukawa T.A., Kupfer D.J., Frank E., and Goodwin G.M. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 361 (2003) 653-661
11. Hylan T.R., Buesching D.P., and Tollefson G.D. Health economic evaluations of antidepressants: a review. Depress Anxiety 7 (1998) 53-64
12. Lawrenson R.A., Tyrer F., Newson R.B., and Farmer R.D. The treatment of depression in UK general practice: selective serotonin reuptake inhibitors and tricyclic antidepressants compared. J Affect Disord 59 (2000) 149-157
13. Mackay F.J., Dunn N.R., Wilton L.V., Pearce G.L., Freemantle S.N., and Mann R.D. A comparison of fluvoxamine, fluoxetine, sertraline and paroxetine examined by observational cohort studies. Pharmacoepidemiol Drug Saf 6 (1997) 235-246
14. Mamdani M.M., Parikh S.V., Austin P.C., and Upshur R.E. Use of antidepressants among elderly subjects: trends and contributing factors. Am J Psychiatry 157 (2000) 360-367
15. McLaughlin T.P., Eaddy M.T., and Grudzinski A.N. A claims analysis comparing citalopram with sertraline as initial pharmacotherapy for a new episode of depression: impact on depression-related treatment charges. Clin Ther 26 (2004) 115-124
16. Melfi C.A., Chawla A.J., Croghan T.W., Hanna M.P., Kennedy S., and Sredl K. The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression. Arch Gen Psychiatry 55 (1998) 1128-1132
17. Menting J.E., Honig A., Verhey F.R., Hartmans M., Rozendaal N., de Vet H.C., and van Praag H.M. Selective serotonin reuptake inhibitors (SSRIs) in the treatment of elderly depressed patients: a qualitative analysis of the literature on their efficacy and side-effects. Int Clin Psychopharmacol 11 (1996) 165-175
18. Moride Y., Du Fort G.G., Monette J., Ducruet T., Boivin J.F., Champoux N., and Crott R. Suboptimal duration of antidepressant treatments in the older ambulatory population of Quebec: association with selected physician characteristics. J Am Geriatr Soc 50 (2002) 1365-1371
19. Mullins C.D., Shaya F.T., Meng F., Wang J., and Harrison D. Persistence, switching, and discontinuation rates among patients receiving sertraline, paroxetine, and citalopram. Pharmacotherapy 25 (2005) 660-667
20. OCCETS - Office Canadien de Coordination de l'Evaluation des Technologies de la Santé. Evaluation clinique et économique des inhibiteurs spécifiques du recaptage de la sérotonine dans les cas de dépression grave (1998), OCCETS, Ottawa
21. Polsky D., Onesirosan P., Bauer M.S., and Glick H.A. Duration of therapy and health care costs of fluoxetine, paroxetine, and sertraline in 6 health plans. J Clin Psychiatry 63 (2002) 156-164
22. Sheehan D.V., Eaddy M.T., Shah M.B., and Mauch R.P. Differences in total medical costs across the SSRIs for the treatment of depression and anxiety. Am J Manag Care 11 (2005) S354-361
23. Von Korff M., Wagner E.H., and Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol 45 (1992) 197-203
24. Wilson K., and Mottram P. A comparison of side effects of selective serotonin reuptake inhibitors and tricyclic antidepressants in older depressed patients: a meta-analysis. Int J Geriatr Psychiatry 19 (2004) 754-762